244 related articles for article (PubMed ID: 31572792)
1. R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T.
Kim J; Moestue SA; Bathen TF; Kim E
Tomography; 2019 Sep; 5(3):308-319. PubMed ID: 31572792
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
Kim J; Kim E; Euceda LR; Meyer DE; Langseth K; Bathen TF; Moestue SA; Huuse EM
J Magn Reson Imaging; 2018 Jun; 47(6):1589-1600. PubMed ID: 29205621
[TBL] [Abstract][Full Text] [Related]
3. Effect of T2* correction on contrast kinetic model analysis using a reference tissue arterial input function at 7 T.
Zhang J; Freed M; Winters K; Kim SG
MAGMA; 2015 Dec; 28(6):555-63. PubMed ID: 26239630
[TBL] [Abstract][Full Text] [Related]
4. Flow versus permeability weighting in estimating the forward volumetric transfer constant (K
Li CH; Chen FH; Schellingerhout D; Lin YS; Hong JH; Liu HL
Magn Reson Imaging; 2017 Feb; 36():105-111. PubMed ID: 27989901
[TBL] [Abstract][Full Text] [Related]
5. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging.
Li Z; Sun J; Chen L; Huang N; Hu P; Hu X; Han G; Zhou Y; Bai W; Niu T; Yang X
J Magn Reson Imaging; 2016 Jul; 44(1):98-104. PubMed ID: 26707910
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma.
Hauge A; Gaustad JV; Huang R; Simonsen TG; Wegner CS; Andersen LMK; Rofstad EK
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):666-676. PubMed ID: 30858145
[TBL] [Abstract][Full Text] [Related]
8. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses.
Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
Radiat Oncol; 2020 Apr; 15(1):79. PubMed ID: 32293487
[TBL] [Abstract][Full Text] [Related]
9. The effects of intravoxel contrast agent diffusion on the analysis of DCE-MRI data in realistic tissue domains.
Woodall RT; Barnes SL; Hormuth DA; Sorace AG; Quarles CC; Yankeelov TE
Magn Reson Med; 2018 Jul; 80(1):330-340. PubMed ID: 29115690
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast enhanced MRI parameters and tumor cellularity in a rat model of cerebral glioma at 7 T.
Aryal MP; Nagaraja TN; Keenan KA; Bagher-Ebadian H; Panda S; Brown SL; Cabral G; Fenstermacher JD; Ewing JR
Magn Reson Med; 2014 Jun; 71(6):2206-14. PubMed ID: 23878070
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Wu L; Lv P; Zhang H; Fu C; Yao X; Wang C; Zeng M; Li Y; Wang X
Magn Reson Imaging; 2015 Jul; 33(6):737-60. PubMed ID: 25169584
[TBL] [Abstract][Full Text] [Related]
13. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
14. Comparison of region-of-interest-averaged and pixel-averaged analysis of DCE-MRI data based on simulations and pre-clinical experiments.
He D; Zamora M; Oto A; Karczmar GS; Fan X
Phys Med Biol; 2017 Sep; 62(18):N445-N459. PubMed ID: 28786402
[TBL] [Abstract][Full Text] [Related]
15. MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.
Cebulla J; Huuse EM; Pettersen K; van der Veen A; Kim E; Andersen S; Prestvik WS; Bofin AM; Pathak AP; Bjørkøy G; Bathen TF; Moestue SA
Br J Cancer; 2015 Feb; 112(3):504-13. PubMed ID: 25535727
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: Comparison with conventional DCE-MRI.
Zhang J; Winters K; Kiser K; Baboli M; Kim SG
PLoS One; 2020; 15(6):e0234520. PubMed ID: 32520950
[TBL] [Abstract][Full Text] [Related]
17. Signal intensity form of the Tofts model for quantitative analysis of prostate dynamic contrast enhanced MRI data.
Fan X; Chatterjee A; Medved M; Oto A; Karczmar GS
Phys Med Biol; 2021 Jan; 66(2):025002. PubMed ID: 33181487
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.
Øvrebø KM; Ellingsen C; Hompland T; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):604-11. PubMed ID: 22671573
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast enhanced MRI monitoring of primary proton and carbon ion irradiation of prostate cancer using a novel hypofractionated raster scan technique.
Bonekamp D; Wolf MB; Edler C; Katayama S; Schlemmer HP; Herfarth K; Röthke M
Radiother Oncol; 2016 Aug; 120(2):313-9. PubMed ID: 27237059
[TBL] [Abstract][Full Text] [Related]
20. Repeatability and correlations of dynamic contrast enhanced and T2* MRI in patients with advanced pancreatic ductal adenocarcinoma.
Klaassen R; Gurney-Champion OJ; Wilmink JW; Besselink MG; Engelbrecht MRW; Stoker J; Nederveen AJ; van Laarhoven HWM
Magn Reson Imaging; 2018 Jul; 50():1-9. PubMed ID: 29476781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
